Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Methotrexate therapy in polymyositis.

× No keyword cloud information.

22 in total

1. Dermatomyositis and malignancy: a review of the literature.

Authors: R C WILLIAMS
Journal: Ann Intern Med Date: 1959-05 Impact factor: 25.391

2. Skeletal muscle involvement in systemic sclerosis.

Authors: J M Thompson; R Bluestone; E G Bywaters; J Dorling; M Johnson
Journal: Ann Rheum Dis Date: 1969-05 Impact factor: 19.103

3. Polymyositis and dermatomyositis.

Authors: C M PEARSON
Journal: Bull Rheum Dis Date: 1962-02

4. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy.

Authors: J N Whitaker; W K Engel
Journal: N Engl J Med Date: 1972-02-17 Impact factor: 91.245

5. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients.

Authors: R K Winkelmann; D W Mulder; E H Lambert; F M Howard; G R Diessner
Journal: Mayo Clin Proc Date: 1968-08 Impact factor: 7.616

6. Destruction of muscle cultures by lymphocytes from cases of polymyositis.

Authors: S Currie
Journal: Acta Neuropathol Date: 1970 Impact factor: 17.088

7. Daunorubicin treatment of methotrexate pneumonia.

Authors: G Pasquinucci; P Ferrara; R Castellari
Journal: JAMA Date: 1971-06-21 Impact factor: 56.272

8. Methotrexate therapy and pulmonary disease.

Authors: I R Schwartz; M K Kajani
Journal: JAMA Date: 1969-12-08 Impact factor: 56.272

9. Pneumonia and methotrexate.

Authors: J H Robertson
Journal: Br Med J Date: 1970-04-18

10. Severe pneumonitis occurring during methotrexate therapy. Re- port of two cases.

Authors: G C Goldman; S L Moschella
Journal: Arch Dermatol Date: 1971-02

14 in total

Review 1. Rheumatology.

Authors: R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal: Postgrad Med J Date: 1991-02 Impact factor: 2.401

2. Idiopathic inflammatory myopathy: treatment options.

Authors: Stephen J DiMartino
Journal: Curr Rheumatol Rep Date: 2008-08 Impact factor: 4.592

Review 3. Recognition and management of myositis.

Authors: P Cherin
Journal: Drugs Date: 1997-07 Impact factor: 9.546

4. Indications for intravenous gammaglobulin therapy in inflammatory myopathies.

Authors: P Cherin; S Herson
Journal: J Neurol Neurosurg Psychiatry Date: 1994-11 Impact factor: 10.154

Review 5. Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors: G L Craig; W W Buchanan
Journal: Drugs Date: 1980-12 Impact factor: 9.546

Review 6. Clinical use of immunosuppressive drugs: part I.

Authors: N L Gerber; A D Steinberg
Journal: Drugs Date: 1976 Impact factor: 9.546

7. The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors: Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal: J Neurol Date: 2004-07 Impact factor: 4.849

8. The treatment of disseminated vasculitis with methotrexate.

Authors: M S Mitchell; R H Gifford; J R Bertino; J D Kenney; S E Malawista
Journal: Inflammation Date: 1976-06 Impact factor: 4.092

9. Dermatomyositis: observations on the use of immunosuppressive therapy and review of literature. Cairo--Glasgow study group.

Authors: A El-Ghobarey; G Balint; K de Ceulaer; W C Dick; W W Buchanan; T Hadidi; T A Hassan
Journal: Postgrad Med J Date: 1978-08 Impact factor: 2.401

10. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease.

Authors: D G Scott; P A Bacon
Journal: Thorax Date: 1980-10 Impact factor: 9.139